Dyslipidemia is common in cancer 👫—driven by the disease, treatments, and LS changes—and can worsen both CV risk and cancer outcomes. Lipid monitoring should be routine ◀️,↔️, and▶️ therapy. Guideline-based management and close cardio-oncology collaboration are 🗝️ #ILEP2025

ESC Board Cardio oncology meeting today. Shaping the future of Cardio-Oncology. The conference starts tomorrow. Do join us !

Let’s start💣💥

💣💣💣‼️ #ESCardioOnco2025 New ESC journal: EHJ-CardioOncology will arrive in 2026 😱 European Society of Cardiology Journals

🔬🧫Join the Basic and Traslational Research in Cardio-Oncology session: preclinical models and future perspectives in anthracycline-induced cardiovascular toxicity and so much more #Florence #ESCardioOnco2025 European Society of Cardiology European Society of Cardiology Journals Teresa López Fdez dineshpmcc

1 in 3 cancer patients may experience serious cardiovascular side effects from treatment. For the first time, experts from cardiology, oncology, haematology, radiology, nursing and more are meeting under one roof at #ESCardioOnco2025 United by a shared mission to improve care

Joint #EHJ and #JACCardioOncology session on scientific novelties from the Cardio-Oncology field 🌍 Science for cardiovascular health of cancer patients 🫀🏥 EHJ Editor-in-Chief European Society of Cardiology Penn Cardiology The Penn Thalheimer Center for Cardio-Oncology JACC Journals

Live from #ESCardioOnco2025 conference in Florence🔈🔈🔈Case-based discussion on management of cancer therapy-related cardiovascular disease ❤️ To know more, join the ESC Council of Cardio-Oncology European Society of Cardiology News European Society of Cardiology Novi Yanti Sari Teresa López Fdez Clara Llamedo, MD International Cardio-Oncology Society

Want to know how to manage patients with CLL undergoing BTK inhibitors? 🏥💊 Join now Room 1 session, only at #ESCardioOnco2025 in Florence🇮🇹 Novi Yanti Sari Pedro Moliner Clara Llamedo, MD Teresa Lopez Fernandez Raul Cordoba, MD, PhD Mike Fradley, MD

Clinical case management Joint session with JACC CardioOncology‼️ #ESCardioOnco2025 JACC Journals

🙏 A heartfelt THANK YOU to all our amazing Social Media Ambassadors, volunteers, and every single attendee who made #ESCardioOnco2025 unforgettable! 💙 Your passion, energy, and commitment helped bring the #cardiooncology community to life ❤️ We can’t wait to see you next year

Assessing the Severity and Risks of ICI-Associated Myocarditis: Key Clinical Indicators in #EHJ! academic.oup.com/eurheartj/adva… #EHJ #cardiotwitter #myocarditis #oncology @ESC_journals European Society of Cardiology

An eye-opener review in Nature Cancer Neoadjuvant immunotherapy is transforming cancer care 🚀! ✅Now proven superior to adjuvant in trials & preclinical studies, it’s SOC in several tumors. 🔝Future focus: combos vs mono, adjuvant after neoadjuvant, & predictive biomarkers

The European Society of Cardiology Journals Family will have a new addition at the beginning of 2026 – the European Heart Journal - Cardio-Oncology. This exciting new publication will need an Editor-in-Chief – and we will soon be announcing the call for applications. If you want to receive updates, make

🚨The new COOL Group of the ESC Council of Cardio-Oncology has been presented in Florence💣🚀 Great news for the young community of Cardio-Oncologists! Want to know more? Read soon the inaugural paper 📝in the #EHJ 🌍🫀Mirabel Mariana Novi Yanti Sari EHJ Editor-in-Chief Teresa Lopez Fernandez European Society of Cardiology

Bridging the gap between #ESCGuidelines and real-world practice Eva Prescott shares how many countries value #ESCGuidelines — but struggle to implement them due to cost, infrastructure, or training barriers. A new methodology pilot is being developed by the ESC to bring more

Congratulations Jennifer and Anthony on this important study !#cardioonc #Cardiooncology #cancer #oncology #breastcancer #cardiology #medtwitter #cardiotwitter OncoDaily International Cardio-Oncology Society Oncology Brothers Breast Cancer Now Breastcancer.org

Using Danish population-based registries, #JACCCardioOnc study found elevated long-term #CVrisk in cancer survivors post systemic therapy 🔹HF/cardiomyopathy (HR 1.08) 🔹#VTE (HR 1.50) 🔹#Myocarditis/pericarditis (HR 1.30) 🔹Kidney failure (HR 1.17) 🔗 jacc.org/doi/10.1016/j.…